CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD

Ann Clin Transl Neurol. 2018 May 26;5(7):883-887. doi: 10.1002/acn3.584. eCollection 2018 Jul.

Abstract

Creutzfeldt-Jakob disease and Alzheimer's disease are characterized by the presence of elevated total-Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho-Tau epitopes (non-P-Tau) in the discrimination between both diseases. Non-P-Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt-Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total-Tau (90%), P-Tau (62%) and 14-3-3 (91%).

Grant support

This work was funded by Innovative Medicines Initiative Joint Undertaking grant 115372; Spanish Ministry of Health ‐ Instituto Carlos III grant CP16/00041; Federal Ministry of Health of Germany grant 1369‐341; European Union's Seventh Framework Program grant FP7/2007‐2013; EFPIA companies’ in kind contribution grant .